Exelixis (EXEL) concentration risks

The company's disclosed concentration profile is defined by a single, high-share product dependency: sales related to cabozantinib account for the majority of revenues, a high-share structural exposure by disclosed size. The character is mixed — it is structural in that cabozantinib is the company's flagship commercial asset whose approved indications span multiple oncology settings, but it also carries dependency characteristics because the entire commercial revenue base flows through a single molecular entity. Any clinical, regulatory, safety, or competitive setback that impairs cabozantinib's market position would directly affect the majority of the company's top line. The mixed character designation is appropriate because the product's breadth of approvals across indications provides some buffer relative to a single-indication asset — label expansions add revenue streams and reduce the risk that any one tumor type's dynamics define the whole. Nevertheless, a generic entry event, a significant new competitor, or an unexpected safety signal would compress revenue in a way that cannot be offset by the rest of the product portfolio within a meaningful investment horizon. No customer, geographic, or supplier concentrations are separately disclosed. The product concentration is therefore the singular and dominant risk factor in the disclosed profile. Investors should track the competitive dynamics in each of cabozantinib's approved indications, pipeline diversification progress, and any signals on the intellectual property timeline as the variables most likely to move the investment outlook.

For the engine’s reasoning on EXEL’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.